(15352506), C. A., (15352509), A. B., (15352512), R. S., (15352515), M. G., (15352518), A. C., (15086287), D. R., . . . (15352566), C. C. (2025). Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Čikaški stil citiranja (17. izdanje)(15352506), Carlotta Antoniotti, et al. Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer. 2025.
MLA način citiranja (9. izdanje)(15352506), Carlotta Antoniotti, et al. Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer. 2025.